Jump to content

NICE to reconsider Alimta ruling in UK !!!!


Recommended Posts

NICE to reconsider Alimta ruling


The National Institute of Health and Clinical Excellence (NICE) has said it is to reconsider its decision that a drug for asbestos-related lung cancer should not be available on the NHS.

Alimta is used to treat mesothelioma, a type of cancer mainly caused by exposure to asbestos. It is currently available in Scotland where it has been approved by national regulators.

NICE said it will reconsider the decision following an appeal by the drug's manufacturer, Eli Lilly. Cancer Research UK welcomed the announcement.

"Alimta is the only licensed therapy for the treatment of unresectable malignant pleural mesothelioma in the UK," said Professor John Toy of Cancer Research UK.

"The treatment has been shown to improve survival in randomised trials and is used around the world.

"The majority of mesothelioma cases arose as a result of workplace negligence and, as such, we believe that patients should be entitled to the best care available."

He added that due to restrictions on the use of asbestos, the number of people with mesothelomia is expected to decline sharply from 2015 and an alternative treatment is unlikely to be developed between now and then.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.